Description
NEW BHS GUIDELINES ON THE MANAGEMENT OF DLBCL
Article: NEW BHS GUIDELINES ON THE MANAGEMENT OF DLBCL
€3.03
Related products
-
Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer
€3.03 Add to cart -
Article: INTRODUCTION
€3.03 Add to cart -
Article: Highlights in breast cancer
€3.03 Add to cart -
1 year subscription print edition of the Belgian Journal of Hematology (BJH)
€209.83 Add to cart
Reviews
There are no reviews yet.